Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LATS1 | O95835 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12757192 | 0.88 | MEN1 (0.48) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL2743933 | 0.87 | MEN1 (0.47) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL1232910 | 0.87 | BCHE (0.52) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL204050 | 0.86 | KMT2A (0.41) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL5456992 | 0.85 | MEN1 (0.44) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL1232778 | 0.85 | STK17B (0.47) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL30503514 | 0.85 | BRD4 (0.47) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL1034070 | 0.85 | BRD4 (0.47) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL29136642 | 0.85 | HDAC1 (0.48) | MEN1KMT2ANPC1GAARAB9A | |
| SCHEMBL29475728 | 0.85 | BRD4 (0.47) | MEN1KMT2ANPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| WO-2022147576-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022011043-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION (US) | 2022-01-13 | — | — | WO | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | MEN1 3475/4885KMT2A 1143/4885NPC1 1683/4885 |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | MEN1 4112/4885KMT2A 3293/4885NPC1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.